SALES@REPORTOCEAN.COM
 +1 888 212 3539 (US - TOLL FREE)    +91 999 711 2116 (REST OF WORLD)
`

Assessment of Covid-19 Impact!!! Get FREE Updated report copy with market revised forecasts and anaysis highlighting shift in business startegies by key players to reinforce their industry position

Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region - North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]

Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region - North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]

Published date: 31-08-2019  Region: Global  Pages: 80  Format: Pdf  Publisher Name: Rockville Research SKU: RO1/119/1058

INDUSTRY INSIGHTS
According to a new report by Rockville Research, the global psoriasis treatment market is estimated to be valued at US$ 27 billion in the year 2025, growing at a CAGR of 8.9% in the period 2019 to 2025. Growth of the market is driven by factors such as rising incidences of the autoimmune diseases, changing lifestyle, ageing population, increasing availability of biologics and biosimilars and growing awareness about the disease.
Psoriasis is a complex, chronic, inflammatory skin disorder that is characterized by itchy skin lesions. It involves hyperproliferation of the keratinocytes which leads to substantial increase in in the epidermal cell turnover rate.
Psoriasis therapeutics market is expected to witness substantial uptake of Biosimilars for currently marketed biologics. The market is expected to get slew of these novel products in the upcoming years. Currently, there are very few biosimilars approved for the treatment of psoriasis and psoriatic arthritis.

REPORT SCOPE
This report "Global Psoriasis Treatment Market [By Drug Classes - (TNF-alpha) Inhibitors, Interleukin (IL) Inhibitors & T-cell Inhibitors; By Region - North America (The US), Europe (The UK & Germany) and Asia Pacific (Japan) - Outlook 2025]" provides a detailed analysis of the global psoriasis therapeutics market from qualitative and quantitative outlooks during the forecast period across various therapeutic classes. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.
Parameter Description
Base year 2016
Forecast period 2019 - 2025
Market sizing Revenue in US$ Billions & CAGR for the period 2019 to 2025
Country coverage The US, The UK, Germany & Japan
Vendor scope AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, Inc.
Report coverage Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

SEGMENTS COVERED
The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, Rockville Research has segmented global psoriasis therapeutics market report has been segmented on the basis of drug classes and region:-
Therapeutic Class Outlook, Revenue (2017 - 2025E, US$ Billions)
> Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
> Interleukin (IL) Inhibitors
> T-cell Inhibitors
Regional Outlook, Revenue (2017 - 2025E, US$ Billions)
> North America
> Europe
> Asia Pacific
Country Outlook, Revenue (2017 - 2025E, US$ Billions)
> The US
> The UK
> Germany
> Japan
Vendors Outlook, Revenue (2013 - 2022E, US$ Billions)
> AbbVie Inc.
> Amgen Inc.
> Johnson & Johnson
> Novartis AG
> Eli Lilly & Company, Inc.
Target Audience
> Psoriasis Drug Manufacturers
> Chemical Suppliers
> End Users
> Research Professionals
> Healthcare Consultancies
> Regulatory Bodies
Key questions answered in the report
> Historical market size of migraine therapeutics from 2016 to 2018 in US$ Billions.
> Projected market growth in the forecasted period 2019 to 2025 with estimated revenue for each year in US$ Billions.
> Revenue forecasts of major psoriasis therapeutics in the period 2016 to 2025 in US$ Billions.
> Regional and country of migraine therapeutics in the period 2017 to 2025 in US$ Billions.
> Market drivers, restraints and industry trends that has impact on revenue.
> Profiling of major companies with detailed analysis of major psoriasis therapeutics approved for marketing as well as in pipeline.
Customization
We provide customization of the study in order to provide specific information as sought by the client.

1. Executive Summary
2. Research Methodology
3. Psoriasis
3.1 Overview
3.1.1 Symptoms
3.1.2 Causes
3.2 Types
3.2.1 Plaque psoriasis
3.2.2 Guttate psoriasis
3.2.3 Pustular psoriasis
3.2.4 Inverse psoriasis
3.2.5 Erythrodermic psoriasis
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Products
4.2.2 Market Share by Therapeutic Class
4.2.3 Market Share by Mode of Administration
4.2.4 Market Share by Region
5. Drug Analysis
5.1 Biologics
5.1.1 Tumor necrosis factor-alpha (TNF-alpha) Inhibitors
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.1.2 Interleukin (IL) Inhibitors
5.1.2.1 Overview
5.1.2.2 Market Sizing (Actual & Forecasted)
5.1.3 T-cell Inhibitors
5.1.3.1 Overview
5.1.3.2 Market Sizing (Actual & Forecasted)
6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 The US
6.1.2.1 Market Sizing (Actual & Forecasted)
6.1.2.2 Market Share by Therapeutic Class
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 Japan
6.3.2.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 Increasing Adoption of Interleukin (IL) Inhibitors
7.1.2 Uptake of Biosimilars
7.1.3 Patent Expirations
7.1.4 Mergers & Acquisitions
7.2 Growth Drivers
7.2.1 Rising Incidences of Autoimmune Diseases
7.2.2 Changing Lifestyle
7.2.3 Ageing Population
7.2.4 Increasing Availability of Biologics & Biosimilars
7.2.5 Growing Awareness
7.3 Challenges
7.3.1 Stringent Regulations
7.3.2 Side-effects of Oral Drugs
7.3.3 High Cost of Drugs
8. Competitive Landscape
8.1 Financial Analysis
8.2 Market Share Analysis
9. Company Profiles
9.1 AbbVie Inc.
9.2 Amgen Inc.
9.3 Johnson & Johnson
9.4 Novartis AG
9.5 Eli Lilly & Company

Figure 1: Rockville Research - Research Methodology
Figure 2: Illustration of Psoriasis
Figure 3: Global Psoriasis Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 4: Global Psoriasis Drugs Market Share by Products (2018)
Figure 5: Global Psoriasis Drugs Market Share by Therapeutic Class (2018)
Figure 6: Global Psoriasis Treatment Market Share by Mode of Administration (2018)
Figure 7: Global Psoriasis Market Share by Region (2018)
Table 1: Selected New Drugs against Psoriasis (phase III mainly)
Table 2: Psoriasis Treatment - Oral Drugs
Table 3: Psoriasis Drugs - Competitive Landscape
Table 4: Biologics Treatment Comparison Chart for Psoriasis
Figure 8: FDA Approval Timeline of Psoriasis Biological/ Small Molecule Agents
Table 5: Anti-TNF product profiles and sales
Figure 9: Global Psoriasis Drugs - TNF-alpha Inhibitors Market Size by Value, 2017-25E (US$ Billions)
Figure 10: Global Psoriasis Drugs - Interleukin (IL) Inhibitors Market Size by Value, 2017-25E (US$ Billions)
Figure 11: Global Psoriasis Drugs - T-cell Inhibitors Market Size by Value, 2017-25E (US$ Billions)
Figure 12: North America Psoriasis Drugs Market Size by Value, 2018-25E (US$ Billions)
Figure 13: The US Psoriasis Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 14: The US Psoriasis Drugs Market Share by Therapeutic Class (2018)
Figure 15: Europe Psoriasis Drugs Market Size by Value, 2018-25E (US$ Billions)
Figure 16: The UK Psoriasis Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 17: Germany Psoriasis Drugs Market Size by Value, 2017-25E (US$ Billions)
Figure 18: Asia Pacific Psoriasis Drugs Market Size by Value, 2018-25E (US$ Billions)
Figure 19: The UK Psoriasis Drugs Market Size by Value, 2017-25E (US$ Billions)
Table 6: Psoriasis Drugs Biosimilars
Table 7: Patent Expirations of Psoriasis Drugs
Table 8: Mergers & Acquisitions in Psoriasis Drugs Market
Figure 20: Global Autoimmune Diseases Incidences, 2014-18 (Millions)
Figure 21: Global Ageing Population (Aged 65 Years and above), 2012-18 (Millions)
Figure 22: Market Penetration of Biologics in the US & EU
Table 9: Global Psoriasis Drugs Manufacturers Revenue Forecast, 2018-23E (US$ Billions)
Table 10: Global Psoriasis Drugs Manufacturers Financial Analysis (2018)
Figure 21: Global Psoriasis Drugs Market Share by Brands (2018)
Figure 22: AbbVie Inc. Revenue by Business Segment (FY2018)
Table 11: AbbVie Inc. - Psoriasis Drugs Approved for Marketing
Table 12: AbbVie Inc. - Psoriasis Drugs in Pipeline
Figure 23: AbbVie Inc. Net Sales, FY2013-FY2018 (US$ Billion)
Figure 24: Amgen Inc. Revenue by Business Segment (FY2018)
Table 13: Amgen Inc. - Psoriasis Drugs Approved for Marketing
Table 14: Amgen Inc. - Psoriasis Drugs in Pipeline
Figure 25: Amgen Inc. Net Sales, FY2013-FY2018 (US$ Billion)
Figure 26: Johnson & Johnson Revenue by Business Segment (FY2018)
Table 15: Johnson & Johnson - Psoriasis Drugs Approved for Marketing
Table 16: Johnson & Johnson - Psoriasis Drugs in Pipeline
Figure 27: Johnson & Johnson Net Sales, FY2013-FY2018 (US$ Billion)
Figure 28: Novartis AG Revenue by Business Segment (FY2018)
Table 17: Novartis AG - Psoriasis Drugs Approved for Marketing
Table 18: Novartis AG - Psoriasis Drugs in Pipeline
Figure 29: Novartis AG Net Sales, FY2013-FY2018 (US$ Billion)
Figure 30: Eli Lilly & Company Revenue by Business Segment (FY2018)
Table 19: Eli Lilly & Company - Psoriasis Drugs Approved for Marketing
Table 20: Eli Lilly & Company - Psoriasis Drugs in Pipeline
Figure 31: Eli Lilly & Company Net Sales, FY2013-FY2018 (US$ Billion)

All Fields are mandatory*

Name: *
Email Id: *
Job Title: *
Company: *
Phone: *
Country: *
Message: *

PLEASE SELECT A LICENSE TYPE

Single User $1300
Multi User $1600
Corporate User $1800

Related Reports

Scroll to Top